Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization
- PMID: 11796581
- PMCID: PMC127686
- DOI: 10.1128/IAI.70.2.544-550.2002
Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization
Abstract
The efficacy of passive immunization as a postexposure prophylactic measure for treatment of guinea pigs intranasally infected with Bacillus anthracis spores was evaluated. Antisera directed either against the lethal toxin components (PA or LF) or against a toxinogenic strain (Sterne) were used for this evaluation. All antisera exhibited high enzyme-linked immunosorbent assay titers against the corresponding antigens, high titers of neutralization of cytotoxicity activity in an in vitro mouse macrophages cell line (J774A.1), as well as in vivo neutralization of toxicity when administered either directly to Fisher rats prior to challenge with the lethal toxin or after incubation with the lethal toxin. In these tests, anti-LF antiserum exhibited the highest neutralization efficiency, followed by anti-Sterne and anti-PA. The time dependence and antibody dose necessary for conferring postexposure protection by the various antibodies of guinea pigs infected with 25 50% lethal doses of Vollum spores was examined. Rabbit anti-PA serum was found to be the most effective. Intraperitoneal injections of anti-PA serum given 24 h postinfection protected 90% of the infected animals, whereas anti-Sterne and anti-LF were less effective. These results further emphasizes the importance of anti-PA antibodies in conferring protection against B. anthracis infection and demonstrated the ability of such antibodies to be effectively applied as an efficient postexposure treatment against anthrax disease.
Figures
Similar articles
-
The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.Microbiology (Reading). 2001 Jun;147(Pt 6):1677-1685. doi: 10.1099/00221287-147-6-1677. Microbiology (Reading). 2001. PMID: 11390699
-
A novel live attenuated anthrax spore vaccine based on an acapsular Bacillus anthracis Sterne strain with mutations in the htrA, lef and cya genes.Vaccine. 2017 Oct 20;35(44):6030-6040. doi: 10.1016/j.vaccine.2017.03.033. Epub 2017 Mar 23. Vaccine. 2017. PMID: 28342664
-
Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.Infect Immun. 2009 Mar;77(3):1197-207. doi: 10.1128/IAI.01217-08. Epub 2008 Dec 29. Infect Immun. 2009. PMID: 19114543 Free PMC article.
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
-
Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol. 2009 Feb;4(1):35-43. doi: 10.2217/17460913.4.1.35. Future Microbiol. 2009. PMID: 19207098 Free PMC article. Review.
Cited by
-
Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen.J Infect Dis. 2006 Mar 1;193(5):625-33. doi: 10.1086/500148. Epub 2006 Feb 2. J Infect Dis. 2006. PMID: 16453257 Free PMC article.
-
Monoclonal antibody therapies against anthrax.Toxins (Basel). 2011 Aug;3(8):1004-19. doi: 10.3390/toxins3081004. Epub 2011 Aug 15. Toxins (Basel). 2011. PMID: 22069754 Free PMC article. Review.
-
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.Microbiol Mol Biol Rev. 2004 Dec;68(4):617-29. doi: 10.1128/MMBR.68.4.617-629.2004. Microbiol Mol Biol Rev. 2004. PMID: 15590776 Free PMC article. Review.
-
A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.Vaccine. 2008 Oct 9;26(43):5494-502. doi: 10.1016/j.vaccine.2008.07.062. Epub 2008 Aug 12. Vaccine. 2008. PMID: 18703110 Free PMC article.
-
Anamnestic protective immunity to Bacillus anthracis is antibody mediated but independent of complement and Fc receptors.Infect Immun. 2008 May;76(5):2177-82. doi: 10.1128/IAI.00647-07. Epub 2008 Mar 3. Infect Immun. 2008. PMID: 18316379 Free PMC article.
References
-
- Brachman, P. S., S. A. Plotkin, F. H. Bumford, and M. M. Atchison. 1960. An epidemic of inhalation anthrax: the first in the twentieth century. Am. J. Hyg. 72:6–23. - PubMed
-
- Bradaric, N., and V. Punda-Polic. 1992. Cutaneous anthrax due to penicillin–resistant Bacillus anthracis transferred by an insect bite. Lancet 340:306–307. - PubMed
-
- Cohen, S., I. Mendelson, Z. Altboum, D. Kobiler, E. Elhanany, T. Bino, M. Leitner, I. Inbar, H. Rosenberg, Y. Gozes, R. Barak, M. Fisher, C. Korman, B. Valan, and A. Shafferman. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68:4549–4558. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases